Biocompatible Osmium Telluride-Polypyrrole Nanocomposite Material: Application in Prostate Specific Antigen Immunosensing

Prostate cancer is a dominant global threat to society. It affects nearly 4000 men in South Africa annually, making it the second most threatening cancerous disease after lung cancer. A potential serological biomarker to monitor early diagnosis of prostate cancer is prostate specific antigen (PSA). We used the PSA biomarker in our work to develop an extremely sensitive electrochemical immunosensor to achieve low detection limits. The fabrication steps followed with the combination of thioglycolic acid capped osmium telluride quantum dots (TGA-OsTe(2)QD)-polypyrrole (PPy) nanocomposite and prostate specific antigen modified on a glassy carbon electrode. The UV-Vis signatures of TGA-OsTe(2)QD-PPy showed an absorption band at 262 nm which is attributed to the PPy and TGA-OsTe(2)QD composite. This band corresponds to the energy band gap of 4.4 and 5.4 eV. The CV responses of BSA|Ab|TGA-OsTe(2)QD|PPy|GCE modified electrode to prostate specific antigen (PSA) was studied within a range of 0-16 ng/mL PSA that was linear, herein referred to as liner range (LR), which produced a limit of detection (LOD) value of 0.36 ng/mL PSA. The values of the immunosensor's calibration parameters (LR and LOD) make them suitable for real sample application, due to their coverage of the PSA concentration range (0-14 ng/mL) that is of clinical importance.

Automated summary

Prostate cancer is a major global threat, with PSA serving as a potential biomarker for early diagnosis. An extremely sensitive electrochemical immunosensor was developed with a detection limit of 0.36 ng/mL, making it suitable for clinical applications.